


P2018

Preceptorship Barcelona 2018

Preceptorship Barcelona 2018
*Striving and Building for Excellence
in Immunodermatology*



“STATE OF THE ART
IN THE MANAGEMENT
OF CHRONIC URTICARIA“



Cordinators

Giménez-Arnau, Ana M.

Hospital del Mar. IMIM.

Universitat Autònoma. Barcelona

Faculty

Curto-Barredo, Laia

Hospital del Mar

Deza, Gustavo

Hospital del Mar

Figueras, Ignasi

Hospital de Bellvitge

Spertino, Jorge

Hospital de San Pau

Egyptian speaker

Magdy Ragab

Hoda Mounib

Introduction Objectives

Patients with chronic urticaria develop wheals, angioedema, or both almost daily, and their disease flares are accompanied by specifically cutaneous symptoms such as itching. Renewed interest in this chronic condition grew out of several scientific and societal events.

Urticaria is a common complaint in routine dermatology practice. Any dermatologist should be able to diagnose the type of urticaria, assess disease activity, order any tests necessary for differential diagnosis (e.g., to identify urticarial vasculitis, autoinflammatory syndromes, etc.), and explain a testing protocol and treatment plan to a patient.

Nevertheless the physician who specializes in the urticaria management ideally working in referral units must have the skills to confirm an initial diagnosis, evaluate severity and the impact of an individual's clinical picture, and order the functional tests necessary to establish etiologic factors and intensity case by case. This approach makes it possible to monitor the efficacy and safety of treatments and at the same time to take care to inform and educate the patient appropriately.

Actually some unmet needs should be addressed,

1. Rational to treat our patients based in the pathogenic knowledge
2. Identify patients suffering of Chronic Urticaria in the health system
3. Emergency protocols of Urticaria and Angioedema
4. Management the patient in our own clinical consultation
5. Management of the Urticaria patients based in the update guidelines
6. What we have learned managing our patients with biologics
7. The need to work in networks: Chronic Urticaria Centres of Reference and Excellence.

This preceptorship will address and discuss such aspects with the objective to get a minimum consensus,

Number of attendees, ideally no more than 15,

Profile, experienced physicians involved in Urticaria.

18 July 2018 (Wednesday)

Venue: Parc de Recerca Biomèdica

Meeting Room: Charles Darwin – Marie Curie

Chair : Giménez-Arnau

Urticaria : Update on pathogenesis and diagnosis

17:00 – 17:15	Welcome and introduction to the programme	<i>Ana M Giménez-Arnau</i>
17:15 – 17:30	Test	<i>Ana M Giménez-Arnau</i>
17:30 – 18:00	Urticaria pathogenesis - Mechanisms of mast cell degranulation; how they degranulate?	<i>Ana M Giménez-Arnau</i>
18:00 – 18:30	Classification and spectrum of CU and Clinical Phenotypes , What we have learned ?	<i>Laia Curto-Barredo</i>
18:30 – 19:00	Mimickers of urticaria in dermatology: diagnosis and therapy	<i>Ignasi Figueras</i>
19:00 – 19:15	Questions and answers and discussion	<i>All Faculty</i>
19:15 – 19:45	Building the excellence for the best management of your patient with Chronic Urticaria	<i>Ana M Giménez-Arnau</i>

Centers of Reference and Excellence; GA2LEN UCARE

19 July 2018 (Thursday)

Venue: Parc de Recerca Biomèdica

Meeting Room: Charles Darwin – Marie Curie

Chair : Giménez-Arnau

Urticaria : Update on management according with the EAACI-WAO-EDF guidelines 2017

09:00 - 09:10	Welcome and introduction to the program	<i>Ana M Giménez-Arnau</i>
09:10 – 09:30	Triggers and exacerbating factors of Urticaria – Exploratory tools	<i>Laia Curto-Barredo</i>
09:30 – 09:50	Treatment of Chronic Urticaria	<i>Ana M Giménez-Arnau</i>
09:50 – 10:00	Questions and answers	<i>All Faculty</i>
10:00 - 10.30	Coffee break	

10:30 – 11:30	Breakout session / workshop I (2 groups) Group 1: How to diagnose chronic urticaria: Provocation tests, FricTest, TempTest, protocols, documentation Group 2: How can I improve the management of chronic urticaria? Instruments to determine/ monitor disease activity (activity scores), quality of life, and control of disease	<i>Ana M Giménez-Arnau</i> <i>Jorge Spertino</i> <i>Ignasi Figueras</i>
---------------	---	---

10:30 – 11:40 Moving to the main lecture

Chair : Giménez-Arnau

What we've learned from real practice treating patients with Urticaria

11:40– 12:00	What we expect using antihistamines, what's our experience	<i>Laia Curto-Barredo</i>
12:00 - 12:20	What we expect using Omalizumab, what's our experience	<i>Ana M Giménez-Arnau</i>
12:20 – 12:40	What we can expect from other available treatments for Chronic Urticaria	<i>Jorge Spertino</i>
12:40 – 13:00	Round table: questions and answers	<i>All the faculty</i>
13:00 – 13:20	Local networks of specialist in Urticaria benefit the patients. The XURCB , the Catalan experience	<i>Ignasi Figueras</i>
13:20 – 14:00	Lunch	
14:00 – 15:30	Visit to the Department , UCARE Unit	<i>Gustavo Deza</i> <i>Ana M Giménez-Arnau</i>
15:00 – 16:00	Test	<i>Ana M Giménez-Arnau</i>
16:00 – 17:00	From some clinical cases – presentation of clinical cases - three cases The Egyptian experience The difficulty to treat urticaria patients: tips and tricks; questions and answers	<i>All faculty</i> <i>Magdy Ragab</i> <i>Hoda Mounib</i>
17:00 – 17:15	Summary and conclusion Urticaria Meeting	<i>Ana M Giménez-Arnau</i>

“Update on moderate-to-severe psoriasis therapy“

Cordinators

Marta Ferran (Spain)

Hospital del Mar

Faculty (suggested depending on availability)

Fernando Gallardo

Hospital del Mar

Fabiola A Ojeda

Hospital del Mar

Egyptian speaker

Mahira Hamdy Elsayed

20 July 2018 (Friday)

Venue: Parc de Recerca Biomedica

Meeting Room: Charles Darwin – Marie Curie

09:00 - 09:10	Welcome and introduction to the programme	<i>Marta Ferran</i>
09:10 – 09:30	Evaluation of psoriasis and its comorbidities	<i>Mahira Hamdy Elsayed</i>
09:30 – 09:45	Guidelines for treatment of moderate-to-severe psoriasis.	<i>TBC</i>
09:45 – 10:00	Choosing the best treatment for our patient	<i>Marta Ferran</i>
10:00 – 10:10	Questions & Answers	
10:10 – 10:40	Coffee Break	
10:40 – 11:00	First-generation biologic drugs in psoriasis: anti-TNF and ustekinumabTargeting IL-23. From ustekinumab to selective IL-23 blockade.	<i>Marta Ferran</i>
11:00 – 11:20	IL-17 inhibitors. Our experience	<i>Marta Ferran</i>
11:20 – 11:35	New therapies in psoriasis	<i>Fernando Gallardo</i>
11:35 – 11:50	Screening and monitoring in patients initiating biologics	<i>Marta Ferran</i>
11:50 – 12:10	Management of psoriatic arthritis	<i>Fabiola A Ojeda</i>
12:10 – 12:20	Questions & Answers	
12:20 – 13:20	Challenging clinical cases	<i>All faculty Egyptian speakers</i>
13:20 – 13:30	Summary and conclusions	<i>Marta Ferran</i>
13:30 – 14:30	Lunch	